A Comprehensive Update on the Chylomicronemia Syndrome

Area of Science:

• Metabolic Disorders
• Genetics
• Cardiovascular Disease

Background:

• Chylomicronemia syndrome is defined by severe hypertriglyceridemia and fasting chylomicronemia, leading to acute pancreatitis risk.
• It encompasses familial chylomicronemia syndrome (rare, monogenic), multifactorial chylomicronemia syndrome (common, polygenic, exacerbated by lifestyle/medications), and familial partial lipodystrophy.
• Complications include pancreatitis, cardiovascular disease, and non-alcoholic steatohepatitis.

Purpose of the Study:

• To provide a comprehensive overview of chylomicronemia syndrome, including its causes, complications, and management strategies.
• To highlight the distinction between monogenic and multifactorial forms and the role of exacerbating factors.
• To emphasize the importance of prevention through early identification and management of risk factors.

Main Methods:

• Literature review and synthesis of current knowledge on chylomicronemia syndrome.
• Analysis of genetic and environmental factors contributing to hypertriglyceridemia.
• Discussion of current and emerging therapeutic approaches.

Main Results:

• Chylomicronemia syndrome has diverse etiologies, with multifactorial causes being most frequent.
• Numerous lifestyle factors and medications significantly exacerbate hypertriglyceridemia.
• Effective management requires addressing underlying causes, lifestyle modifications, and pharmacological interventions.

Conclusions:

• Chylomicronemia syndrome is a serious condition with significant morbidity, but many cases are preventable.
• Integrated management focusing on genetic predisposition, lifestyle, and medication review is crucial.
• Advancements in pharmacotherapy offer promising future treatments for hypertriglyceridemia.